Online Exclusive Article

Adverse Event Management Strategies

Jessica Mitchell

Taline Khoukaz

Deborah McNeal

Lori Brent

gastrointestinal malignancies, biotherapy/targeted therapy
CJON 2014, 18(2), E19-E25. DOI: 10.1188/14.CJON.E19-E25

Patients with metastatic colorectal cancer (mCRC) frequently experience treatment-related adverse events (AEs), which may lead to nonadherence or discontinuation from their treatment regimen. In the phase 3 CORRECT study, the addition of regorafenib to best supportive care (BSC) significantly increased overall survival and progression-free survival compared with placebo plus BSC in patients with mCRC who had progressed on all approved standard care therapies. Although regorafenib showed an acceptable safety profile, patients experienced treatment-related AEs such as hand-foot skin reaction, hypertension, oral mucositis, diarrhea, fatigue, and liver abnormalities. The goal of this article is to help oncology nurses implement a strategic, proactive approach to AE management in patients mCRC treated with regorafenib. The article reviews the most common AEs associated with regorafenib in patients who participated in the CORRECT study and provides a strategy and practical measures that nurses can apply to AE management. In addition, the article provides direction and guidance for educating patients and their caregivers on recognizing and managing potential side effects of regorafenib.

Members Only
Not a current ONS member or journal subscriber?

Purchase This Article

Receive a PDF to download and print.